首页> 外文期刊>Bone marrow transplantation >Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors
【24h】

Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors

机译:慢性GVHD与从无关供体接受移植的患者中不论干细胞来源如何均具有较低的复发风险

获取原文
获取原文并翻译 | 示例
       

摘要

Chronic GVHD (cGVHD) has been associated with reduced risk of relapse after allo-SCT for onco-hematological disease due to a graft-vs-malignancy effect. Here we retrospectively analyzed a series of 802 adult patients transplanted from unrelated donors and found that cGVHD was associated with significantly lower relapse and that the limited form was associated with a survival advantage: hazard ratio for OS0.63 (0.460.87); P<0.004; this was due to combination of relapse reduction and similar non-relapse mortality with respect to patients without cGVHD. Importantly, the graft-vs-malignancy effect observed here did not differ when PBSC or BM were used as stem cell source, thus suggesting that the protective effect of limited cGVHD is similar after PBSC-or BM-based transplantation. These findings could have practical implications and suggest no qualitative difference between cGVHD occurring after transplantation performed with different stem cell sources.
机译:由于移植物抗恶性肿瘤的作用,慢性GVHD(cGVHD)与同种SCT治疗肿瘤血液系统疾病后复发的风险降低有关。在这里,我们回顾性分析了802例从无关供体移植的成年患者,发现cGVHD与复发率显着降低有关,而有限形式与生存优势有关:OS0.63的危险比(0.460.87)。 P <0.004;这是由于对没有cGVHD的患者减少复发和类似的非复发死亡率的结合。重要的是,当使用PBSC或BM作为干细胞来源时,此处观察到的移植物抗恶性作用没有差异,因此表明有限的cGVHD的保护作用在基于PBSC或BM的移植后是相似的。这些发现可能具有实际意义,并暗示在用不同干细胞来源进行移植后发生的cGVHD之间没有质的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号